Effectiveness of homologous and heterologous BNT162b2 and CoronaVac booster vaccination against severe COVID-19 outcomes
Introduction: Evidence of the waning immunity of coronavirus disease 2019 (COVID-19) primary vaccination, and immune evasion by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has led to the rollout of booster vaccination in many countries. Assessing the effectiveness of b...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Journal of Infection in Developing Countries
2025-01-01
|
| Series: | Journal of Infection in Developing Countries |
| Subjects: | |
| Online Access: | https://jidc.org/index.php/journal/article/view/18946 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Introduction: Evidence of the waning immunity of coronavirus disease 2019 (COVID-19) primary vaccination, and immune evasion by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has led to the rollout of booster vaccination in many countries. Assessing the effectiveness of booster vaccination against severe COVID-19 outcomes is crucial during the transition to endemicity.
Methodology: We conducted a population-based, matched case-control study in Malaysia to estimate the marginal vaccine effectiveness (mVE) of homologous and heterologous BNT162b2 and CoronaVac booster vaccination against COVID-19 related intensive care unit (ICU) admission and death in Delta-predominant and Omicron-predominant periods.
Results: Receipt of a booster vaccination – either homologous or heterologous for CoronaVac, and homologous for BNT162b2 – demonstrated mVE estimates of at least 70% against ICU admission and at least 80% against death, compared to BNT162b2 primary vaccination, in both periods. Overall, the mVE estimates were 10–20 percentage points lower in the Omicron-predominant period than in the Delta-predominant period.
Conclusions: Our study reaffirms that the administration of booster vaccination increases protection against severe COVID-19 outcomes for BNT162b2 and CoronaVac primary vaccination recipients.
|
|---|---|
| ISSN: | 1972-2680 |